Development of Novel Anticancer Pyrazolopyrimidinones Targeting Glioblastoma
ChemMedChem · 2025
DOI: 10.1002/cmdc.202500337 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Kate Byrne und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Food Science and Environmental Health, Technological University Dublin, Grangegorman Lower, Dublin 7, Dublin, D07 ADY7, Ireland. Hauptthemen laut MEDLINE: Glioblastoma, Antineoplastic Agents, Pyrazoles, Pyrimidinones. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fiosraigh Dean of Graduate Research School Award, Science Foundation Ireland.
Abstract (Originalsprache)
Glioblastoma (GBM) is the most common and aggressive malignant grade IV brain tumor and is one of the most difficult types of brain cancer to treat with a high incidence of resistance to traditionally used chemotherapeutics. Pyrazolopyrimidinones are fused nitrogen‐containing heterocyclic systems which are a scaffold in several bioactive drugs and drug candidates. Here, a structure–activity relationship (SAR) study was performed where 23 substituted pyrazolo[1,5‐ α ]pyrimidinones were screened for cytotoxicity against the GBM U‐251 MG cell line and the noncancerous embryonic kidney HEK293 cell line to assess their potential as antiGBM agents capable of selectivity for cancer cells. Through analog synthesis of preliminary HIT compounds with varied structural substituents, a lead compound, 22 , has been identified, which proved capable of inducing significant GBM cell death while having a marginal cytotoxicity against the noncancerous cells. The mode of cell death studies suggested that the structurally varied HIT compounds induced cell death through differential mechanisms including cell membrane permeabilization and mitochondria membrane depolarization‐dependent mechanisms such as necrosis or apoptosis. The results highlight the potential of pyrazolo[1,5‐ α ]pyrimidinones derivatives as a novel anti‐GBM therapy, capable of selectively killing cancer cells. Furthermore, pyrazolo[1,5‐ α ]pyrimidinones provide a scaffold for further development of selective GBM therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Food Science and Environmental Health, Technological University Dublin, Grangegorman Lower, Dublin 7, Dublin, D07 ADY7, Ireland.
- Sustainability and Health Research Hub (SHRH), Technological University Dublin, Grangegorman Lower, Dublin 7, Dublin, D07 ADY7, Ireland.
- Department of Chemistry, Maynooth University, Maynooth, W23 F2H6, Ireland.
- Kathleen Lonsdale Institute for Human Health Research, Maynooth University, Maynooth, W23 F2H6, Ireland.
ORCID-Profile: Gemma K Kinsella
Förderung
- Fiosraigh Dean of Graduate Research School Award
- Science Foundation Ireland
Zitieren
APA
Byrne, K., Bednarz, N., McEvoy, C., Stephens, J. C., Curtin, J. F., & Kinsella, G. K. (2025). Development of Novel Anticancer Pyrazolopyrimidinones Targeting Glioblastoma. ChemMedChem. https://doi.org/10.1002/cmdc.202500337
Vancouver
Byrne K, Bednarz N, McEvoy C, Stephens JC, Curtin JF, Kinsella GK. Development of Novel Anticancer Pyrazolopyrimidinones Targeting Glioblastoma. ChemMedChem. 2025. doi:10.1002/cmdc.202500337
BibTeX
@article{Byrne2025,
author = {Byrne, Kate and Bednarz, Natalia and McEvoy, Ciara and Stephens, John C and Curtin, James F and Kinsella, Gemma K},
title = {Development of Novel Anticancer Pyrazolopyrimidinones Targeting Glioblastoma},
journal = {ChemMedChem},
year = {2025},
doi = {10.1002/cmdc.202500337}
}
EUVIMED